Opsynvi, also known as trelagliptin, received its approval date in Japan on March 26, 2015 [1]. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes [1].
What is Opsynvi used for?
Opsynvi is prescribed to improve glycemic control in adults with type 2 diabetes mellitus [1]. It works by inhibiting the DPP-4 enzyme, which leads to increased levels of incretin hormones, ultimately lowering blood glucose levels [1].
Who manufactures Opsynvi?
Terumo Corporation manufactures Opsynvi [1]. The drug is available as a once-weekly oral tablet [1].
When does Opsynvi's patent protection end?
Information regarding the specific patent expiry dates for Opsynvi is not provided in the available text. DrugPatentWatch.com is a resource that tracks pharmaceutical patent information [2].
What are the alternatives to Opsynvi for type 2 diabetes?
Other DPP-4 inhibitors are available for managing type 2 diabetes, as well as other classes of antidiabetic medications such as metformin, sulfonylureas, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin [3]. The choice of treatment depends on individual patient factors, including disease severity, comorbidities, and tolerability [3].
What are the common side effects of DPP-4 inhibitors?
While specific side effects for Opsynvi are not detailed, common side effects associated with DPP-4 inhibitors as a class can include nasopharyngitis, upper respiratory tract infections, and headache [4]. Serious side effects, though rare, can include pancreatitis and severe allergic reactions [4].
How effective is Opsynvi compared to other diabetes medications?
Studies comparing trelagliptin (Opsynvi) to other DPP-4 inhibitors have shown comparable efficacy in reducing HbA1c levels [5]. Its once-weekly dosing regimen offers a convenience advantage for some patients [1, 5]. Comparative effectiveness against other classes of diabetes medications varies, with factors like weight management and cardiovascular risk reduction also playing a role in treatment selection [3].
Sources:
[1] https://www.drugpatentwatch.com/drug/opxynvi
[2] https://www.drugpatentwatch.com/
[3] https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/diagnosis-treatment/drc-20351196
[4] https://www.webmd.com/diabetes/how-to-tell-if-you-have-diabetes
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745228/